270 related articles for article (PubMed ID: 7674333)
1. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.
Canevari S; Stoter G; Arienti F; Bolis G; Colnaghi MI; Di Re EM; Eggermont AM; Goey SH; Gratama JW; Lamers CH
J Natl Cancer Inst; 1995 Oct; 87(19):1463-9. PubMed ID: 7674333
[TBL] [Abstract][Full Text] [Related]
2. Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re-targeted by a bi-specific monoclonal antibody.
Lamers CH; Bolhuis RL; Warnaar SO; Stoter G; Gratama JW
Int J Cancer; 1997 Oct; 73(2):211-9. PubMed ID: 9335445
[TBL] [Abstract][Full Text] [Related]
3. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.
Luiten RM; Warnaar SO; Sanborn D; Lamers CH; Bolhuis RL; Litvinov SV; Zurawski VR; Coney LR
J Immunother; 1997 Nov; 20(6):496-504. PubMed ID: 9409456
[TBL] [Abstract][Full Text] [Related]
4. Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions.
Canevari S; Mezzanzanica D; Mazzoni A; Negri DR; Ramakrishna V; Bolhuis RL; Colnaghi MI; Bolis G
J Hematother; 1995 Oct; 4(5):423-7. PubMed ID: 8581379
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR.
van Ravenswaay Claasen HH; Eggermont AM; Nooyen YA; Warnaar SO; Fieuren GJ
Gynecol Oncol; 1994 Feb; 52(2):199-206. PubMed ID: 8314139
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients.
Tibben JG; Boerman OC; Massuger LF; Schijf CP; Claessens RA; Corstens FH
Int J Cancer; 1996 May; 66(4):477-83. PubMed ID: 8635863
[TBL] [Abstract][Full Text] [Related]
8. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract][Full Text] [Related]
9. Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival.
Miotti S; Negri DR; Valota O; Calabrese M; Bolhuis RL; Gratama JW; Colnaghi MI; Canevari S
Int J Cancer; 1999 Feb; 84(1):62-8. PubMed ID: 9988234
[TBL] [Abstract][Full Text] [Related]
10. Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation.
Jacobs N; Mazzoni A; Mezzanzanica D; Negri DR; Valota O; Colnaghi MI; Moutschen MP; Boniver J; Canevari S
Cancer Immunol Immunother; 1997 Jul; 44(5):257-64. PubMed ID: 9247560
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study.
Bolhuis RL; Lamers CH; Goey SH; Eggermont AM; Trimbos JB; Stoter G; Lanzavecchia A; di Re E; Miotti S; Raspagliesi F
Int J Cancer Suppl; 1992; 7():78-81. PubMed ID: 1428412
[TBL] [Abstract][Full Text] [Related]
12. Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells.
Pupa SM; Canevari S; Fontanelli R; Ménard S; Mezzanzanica D; Lanzavecchia A; Colnaghi MI
Int J Cancer; 1988 Sep; 42(3):455-9. PubMed ID: 2971021
[TBL] [Abstract][Full Text] [Related]
13. Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice.
Garrido MA; Valdayo MJ; Winkler DF; Titus JA; Hecht TT; Perez P; Segal DM; Wunderlich JR
Cancer Res; 1990 Jul; 50(14):4227-32. PubMed ID: 2142014
[TBL] [Abstract][Full Text] [Related]
14. Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic.
Mezzanzanica D; Canevari S; Colnaghi MI
Int J Clin Lab Res; 1991; 21(2):159-64. PubMed ID: 1815760
[TBL] [Abstract][Full Text] [Related]
15. Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2.
Tibben JG; Boerman OC; Claessens RA; Corstens FH; van Deuren M; de Mulder PH; van der Meer JW; Keijser KG; Massuger LF
J Natl Cancer Inst; 1993 Jun; 85(12):1003-4. PubMed ID: 8496973
[No Abstract] [Full Text] [Related]
16. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibodies and retargeted cellular cytotoxicity: novel approaches to cancer therapy.
Wunderlich JR; Mezzanzanica D; Garrido MA; Neblock DS; Daddona PE; Andrew SM; Zurawski VR; Canevari S; Colnaghi MI; Segal DM
Int J Clin Lab Res; 1992; 22(1):17-20. PubMed ID: 1633315
[TBL] [Abstract][Full Text] [Related]
18. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
[TBL] [Abstract][Full Text] [Related]
19. Antiidiotypic antibodies in ovarian cancer patients treated with the monoclonal antibody B72.3.
Schmolling J; Reinsberg J; Wagner U; Krebs D
Hybridoma; 1995 Apr; 14(2):183-6. PubMed ID: 7590777
[TBL] [Abstract][Full Text] [Related]
20. Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab')2 antibody prolong host survival in a murine xenograft model.
Mezzanzanica D; Garrido MA; Neblock DS; Daddona PE; Andrew SM; Zurawski VR; Segal DM; Wunderlich JR
Cancer Res; 1991 Oct; 51(20):5716-21. PubMed ID: 1833054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
